Changes in anti-PF 4 antibodies in patients with VITT including changes of the antibodies after vaccination against COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025738

Enrollment

100

Registered

2021-07-02

Start date

2021-06-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Y59.9

Interventions

Group 1: Study patients = patients with confirmed VITT after vaccination against COVID-19 with confirmed platelet activating antibodies against PF4. For follow-up of platelet activating antibodies, pa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: VITT with confirmed platelet activating anti-PF4 antibodies

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Changes in antibody titers; endpoint = date of the last, received blood sample of the patient. Antibody titers will be detected with PF4/heparin immuno assay	—

Secondary

Measure	Time frame
Occurrence of new thrombosis and/or thrombocytopenia	—

Countries

Germany

Contacts

Public ContactLinda Schönborn

Abteilung Transfusionsmedizin Greifswald

Linda.Schoenborn@med.uni-greifswald.de+49 3834 865496

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026